Protara Therapeutics

TARANasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$231.561 M

$4.12 +0.49%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$57.4M

Loss-making

Shares outstanding

54,084,378

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#90SurrozenSRZN$297.5M
#91Lineage Cell TherapeuticsLCTX$274.2M
#92Protara TherapeuticsTARA$231.6M
#93CompugenCGEN$227.9M
#94InvivydIVVD$218.0M

Where these numbers come from

Share counts and financials for Protara Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.